Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta. by Sheppard, Olivia et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lipopolysaccharide-induced neuroinflammation induces
presynaptic disruption through a direct action on brain tissue
involving microglia-derived interleukin 1 beta.
Citation for published version:
Sheppard, O, Coleman, M & Durrant, C 2019, 'Lipopolysaccharide-induced neuroinflammation induces
presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta.',
Journal of neuroinflammation, vol. 16, 106 (2019).
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of neuroinflammation
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Feb. 2020
RESEARCH Open Access
Lipopolysaccharide-induced
neuroinflammation induces presynaptic
disruption through a direct action on
brain tissue involving microglia-derived
interleukin 1 beta
Olivia Sheppard1, Michael P. Coleman1,2 and Claire S. Durrant1,2*
Abstract
Background: Systemic inflammation has been linked to synapse loss and cognitive decline in human patients and
animal models. A role for microglial release of pro-inflammatory cytokines has been proposed based on in vivo and
primary culture studies. However, mechanisms are hard to study in vivo as specific microglial ablation is challenging
and the extracellular fluid cannot be sampled without invasive methods. Primary cultures have different limitations as the
intricate multicellular architecture in the brain is not fully reproduced. It is essential to confirm proposed brain-specific
mechanisms of inflammatory synapse loss directly in brain tissue. Organotypic hippocampal slice cultures (OHSCs) retain
much of the in vivo neuronal architecture, synaptic connections and diversity of cell types whilst providing convenient
access to manipulate and sample the culture medium and observe cellular reactions.
Methods: OHSCs were generated from P6-P9 C57BL/6 mice. Inflammation was induced via addition of
lipopolysaccharide (LPS), and cultures were analysed for changes in synaptic proteins, gene expression and protein
secretion. Microglia were selectively depleted using clodronate, and the effect of IL1β was assessed using a specific
neutralising monoclonal antibody.
Results: LPS treatment induced loss of the presynaptic protein synaptophysin without altering PSD95 or Aβ protein
levels. Depletion of microglia prior to LPS application prevented the loss of synaptophysin, whilst microglia depletion after
the inflammatory insult was partially effective, although less so than pre-emptive treatment, indicating a time-critical
window in which microglia can induce synaptic damage. IL1β protein and mRNA were increased after LPS addition, with
these effects also prevented by microglia depletion. Direct application of IL1β to OHSCs resulted in synaptophysin loss
whilst pre-treatment with IL1β neutralising antibody prior to LPS addition prevented a significant loss of synaptophysin
but may also impact basal synaptic levels.
Conclusions: The loss of synaptophysin in this system confirms LPS can act directly within brain tissue to disrupt
synapses, and we show that microglia are the relevant cellular target when all major CNS cell types are present. By
overcoming limitations of primary culture and in vivo work, our study strengthens the evidence for a key role of
microglia-derived IL1β in synaptic dysfunction after inflammatory insult.
Keywords: Organotypic hippocampal slice culture, Lipopolysaccharide, Microglia, IL1β, Synapse, Synaptophysin,
Presynaptic, Alzheimer’s disease
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Background
Neuroinflammation has been linked to synapse loss and
cognitive decline both in humans and in pre-clinical
models, but important questions remain about the cellular
mechanisms that existing experimental systems cannot eas-
ily address. Systemic inflammatory events such as sepsis,
periodontitis, infections, bone fracture and post-operative
trauma can result in sustained high levels of circulating
pro-inflammatory cytokines [1, 2] and have been linked
with long-term cognitive impairment in patients [3–7].
Observations that systemic inflammation accelerates cogni-
tive decline in Alzheimer’s disease [2, 8–10] as well as ex-
acerbating disease processes in other neurodegenerative
disorders [11–13] mean that understanding how inflamma-
tory processes result in synapse loss in the brain is a key
requirement for designing effective therapeutics.
Studies investigating the link between systemic inflam-
mation and changes in the central nervous system
(CNS) in vivo induce systemic inflammation either asep-
tically (via administration of lipopolysaccharide (LPS), a
potent endotoxin found on the cell walls of gram-nega-
tive bacteria [14]) or by inducing sepsis for example via
cecal ligation and puncture [15, 16]. Such studies have
suggested that induction of systemic inflammation can
result in the activation of microglia, increased produc-
tion of pro-inflammatory cytokines such as interleukin
1-beta (IL-1β) and loss of synaptic proteins in the hippo-
campus which coincides with cognitive impairment [16–
23]. Links between mechanisms of synapse loss in Alz-
heimer’s disease and systemic inflammation have also been
explored, with the contradictory findings that LPS adminis-
tration can increase the production of Aβ [20, 24, 25] but
results in enhanced clearance of diffuse plaques from
mouse models of Alzheimer’s disease [26–29]. Whilst in
vivo models have proved useful to model aspects of
neuroinflammatory processes, mechanistic studies explor-
ing how inflammatory insults lead to synaptic alterations
in the brain are constrained by difficulty in determining
which steps take place within the periphery and which
within the brain, by breakdown of the blood-brain barrier
and by limited control over experimental conditions and
observations. Proving the pivotal role of microglia in vivo,
for example, is challenging, as depletion of microglia, or in-
hibition of activation, may also target invading peripheral
immune cells [30]. Similarly, whilst there are reports of in-
creased IL1β production in the hippocampus after micro-
glial activation [15, 16, 18, 19, 23], determining whether
such a change is directly responsible for synaptic deficits is
complicated by difficulty in targeting IL1β antagonising
drugs or neutralising antibodies to the brain and maintain-
ing their levels [31, 32]. As such, many studies seek to ex-
plore proposed mechanisms using primary culture models.
Applying conditioned medium from LPS-activated
microglia cultures to primary hippocampal neurons has
been shown to induce loss of synapses, with this effect
attenuated by the co-application of IL1-receptor antago-
nists or IL1β-neutralising antibodies [16, 33]. Similarly,
direct application of IL1β to primary neuronal cultures
results in loss of synapses [16, 33, 34] and depresses syn-
aptic transmission [35]. However, whilst these studies
provide insight into how microglial activation may result
in synaptic disruption, such systems are, by necessity, an
over-simplification of the CNS environment. Synapses
formed in primary neuronal cultures will differ from those
found in vivo, which form as part of highly structured
connectivity networks and are heavily influenced by resi-
dent glial cells [36–39]. Astrocytes, for example, have been
shown to be involved in the development, support and
elimination of synapses [40, 41], and cross-talk between
neurons in functional circuits regulates synaptic strength
and plasticity [42]. Physically isolating microglia from neu-
rons in such studies also prevents consideration of the role
direct contact between these cell types play in the
formation, maintenance and destruction of synapses
under physiological and pathological conditions [43–46].
Studying microglial responses in isolation from other glial
cells could also mask relevant phenotypes. For example,
whilst conditioned medium from LPS-stimulated micro-
glia resulted in the loss of synapses when applied to neur-
onal culture, treatment with LPS-stimulated astrocyte-
conditioned medium increased synapse formation [16].
Co-culture of astrocytes and microglia has also been
found to alter the response to LPS [47]. Taken together, it
is apparent that there are gaps in the mechanistic explor-
ation of inflammation-induced synaptic disruption that
neither primary culture, in vivo studies, nor even combi-
nations of the two, can address.
Organotypic hippocampal slice cultures (OHSCs),
where thin sections of the hippocampus are main-
tained in culture for several weeks [48–50], represent
a crucial intermediate between in vivo and primary culture
models and offer an excellent opportunity to explore
mechanisms of synaptic disruption in neuroinflammation.
Slice cultures retain hippocampal cytoarchitecture, synap-
tic connections and populations of supporting cell types
in a system isolated from peripheral confounds that is
amenable to experimental manipulation and observation
[48–51]. As multiple slices can be produced from the
same animal, experimental treatments can also be com-
pared to controls from the same biological sample, redu-
cing the number of animals required for effective
experimentation, and ensuring baseline differences be-
tween animals do not mask the effects of experimental
manipulations [50].
In this study, we retest the hypotheses that LPS treat-
ment can disrupt synapses through a direct action on
brain tissue, that this is dependent on microglia and
IL1β, and we test whether such synaptic disruption is
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reversible. We confirm that this occurs in the absence of
significant neuronal cell loss or alterations in Aβ
production. This work highlights a key role of microglial-
derived IL1β in neuroinflammatory synapse loss and tests
the potential for therapeutic intervention and recovery.
Methods
Mice
Wild-type mouse pups (C57BL/6Babr), at age 6–9 days
old were obtained from the breeding colony at the
Babraham Institute. Animal work was approved by the
Babraham Institute Animal Welfare, Experimentation
and Ethics Committee and was performed in accordance
with the Animals (Scientific Procedures) Act 1986 under
Project License PPL 70/7620 and P98A03BF9. All ani-
mals were bred in a specific pathogen-free animal facility
with strict temperature and humidity control. Both gen-
ders were used in experiments.
Organotypic hippocampal slice cultures
OHSCs were cultured according to the interface method
as described previously [48, 49]. Briefly, P6-P9 mouse
pups were humanely sacrificed by cervical dislocation
and their brains rapidly transferred to ice-cold dissection
medium (EBSS + 25 mM HEPES +1× penicillin/strepto-
mycin). Brains were transected at the midline and
glued (Loctite) to a vibratome stage. Three hundred
fifty-micrometre sagittal slices were cut using a Leica
VT1000S vibratome, and the hippocampus and associ-
ated entorhinal cortex dissected out. Slices were plated
on 0.4-μm pore membranes (Millipore: PICM0RG50)
sitting on top of 1 ml of maintenance medium (50%
MEM with Glutamax-1 (Life Tech: 42360-024), 25%
heat-inactivated horse serum (Life Tech: 26050-070),
23% EBSS (Life Tech: 24010-043), 0.65% D-glucose
(Sigma: G8270), 2% penicillin-streptomycin (Life Tech:
15140-122) and 6 units/ml Nystatin (Sigma: N1638)).
Two to four culture dishes per pup were made, depending
on the experimental protocol, with two to three slices
plated per dish. One and 4 days after plating, cultures
underwent a 100% medium exchange, before moving to a
50% weekly exchange thereafter. Cultures were main-
tained in an incubator under high humidity at 37 °C and
5% CO2 for up to 5 weeks.
Treatments
At 2 weeks in vitro, OHSCs were treated with 200 ng/ml
lipopolysaccharide from Escherichia coli O55:B5 (LPS)
(Sigma: L5418) or 20 ng/ml murine interleukin-1β (IL-1β)
(Sigma: I9401) for an additional 7 days. For microglial de-
pletion experiments, OHSCs were treated with 100 μg/ml
clodronate (VWR: 233183) for 24 h prior or 24 h after,
and throughout, LPS treatment. For IL1β-neutralising
experiments, OHSCs were pre-treated with either 1 μg/ml
murine-IL1β-neutralising mouse monoclonal antibody
(Invivogen: mabg-mil1b) or 1 μg/ml mouse IgG isotype
control antibody specific to E. coli β-galactosidase (Invivo-
gen: mabg1-ctrlm) for 24 h prior and throughout LPS
treatment. To assess cell death, OHSCs were incubated
with 1 μg/ml propidium iodide (ThermoFisher Scientific:
P3566) for 15min, washed in EBSS then imaged using a
DMi8 Leica fluorescence microscope.
Western blotting
OHSCs were scraped off the membrane into ice-cold
RIPA buffer (50 mM Tris-HCl, 500 mM NaCl, 1%
Triton-X, 10 nM EDTA, pH 8.0) with protease and phos-
phatase inhibitors (ThermoFisher Scientific: 78442). Slices
underwent probe sonication for 2 × 5 s to completely
homogenise the tissue. Equal amounts of protein were
denatured in Laemelli buffer (with 2-Mercaptoethanol)
and loaded into 4–20% Tris-glycine gels for separation by
SDS-PAGE. Proteins were transferred onto PDVF-FL
prior to blocking in Odyssey blocking buffer for 1 h at
room temperature. Primary antibodies were diluted in 5%
BSA in PBS-T with 0.05% sodium azide, and membranes
were incubated overnight at 4 °C on the shaker. After 3
PBS-T washes, membranes were incubated in 1:10,000
secondary IRDye anti-mouse and anti-rabbit antibodies
(Li-Cor) for 2 h (protected from light), washed with
PBS-T then imaged using a Li-Cor Odyssey CLX system.
Band intensities were normalised to beta iii tubulin (Tuj1)
to control for differences in neuron number. Primary anti-
bodies were used as follows: 1:1000 mouse synaptophysin
(Abcam: ab8049), 1:500 rabbit PSD95 (Abcam: ab18258)
and 1:2500 rabbit Tuj1 (Sigma: T2200).
Immunohistochemistry
Slices remained adhered to membranes whilst fixed for 20
min in 4% PFA and then washed three times in PBS. The
membranes were then cut, and slices were placed in a
24-well plate and blocked for 1 h in blocking solution
(PBS + 0.5% Triton X-100 + 3% goat serum). Slices were
incubated with primary antibody (1:500 Iba-1 (Alpha
Laboratories: 019-19741)) diluted in blocking solution
overnight with shaking at 4 °C. After three PBS washes,
OHSCs were incubated (2 h, room temperature, protected
from light) with Alexa488 or 568 conjugated secondary
antibodies (Life Technologies) diluted 1:250 in blocking
solution. Slices were counterstained with Hoechst (1:5000
in PBS), washed in PBS then mounted on slides to be
imaged via confocal microscopy. Iba1 coverage was
assessed via ImageJ, with the area of Iba1 immunostaining
expressed as a percentage of the total image area.
Quantitative PCR
RNA was extracted from OHSCs using the RNEasy Extrac-
tion Kit (Qiagen: 74104). From this, cDNA was synthesised
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using a Reverse Transcriptase Kit (Quantitect: 205310).
Quantitative PCR was carried out using Brilliant III
Ultra-Fast SYBR Green QPCR Master Mix (Agilent
Technologies: 600882). The following PCR programme
was used on a BIO-RAD CFX96 Real-Time PCR Detection
System with c1000 Touch Thermal cycler: 3min at 95 °C,
40 cycles of 5 seconds at 95 °C and 5 seconds at 60 °C.
Primers for each gene are listed in the table below.
Gene name Forward primer (5′-3′) Reverse primer (5′-3′)
Pgk1 CTAT
CATAGGTGGTGGAGAC
ACAC
TAGGTTGACTTAGGAG
Hprt AGGG
ATTTGAATCACGTTTG
TTTA
CTGGCAACATCAACAG
Ywhaz ACTT
AACATTGTGGACATCG
GGAT
GACAAATGGTCTACTG
Synaptophysin
(SYP)
GATG
TAATCTGGTCAGTGAAG
TAGG
GCTCAGACAGATAAATAG
PSD95 (dlg4) ATTGGAAA
GGGGTAACTCAG
CTTG
GTGATAAAGATGGATGG
IL1β GGAT
GATGATGATAACTGC
CATGGAGA
ATATCACTTGTTGG
APP CAAA
AACTGGTGTTCTTTGC
TGAT
GGATGGATGTGTACTG
ELISA
To determine the level of murine Aβ1–42 or IL1β in
the culture medium, ELISAs were carried out using
commercially available kits (Invitrogen: KMB3441 or R&D
Systems: MLB00C). Medium was collected from slice
cultures at various timepoints throughout LPS or IL-1β
treatment. ELISA was carried out as per the manufac-
turer’s instructions, with absorbance read using a PheraS-
tar FS plate reader.
Statistical analysis
Data was analysed using GraphPad Prism Software.
Statistical tests were chosen to match the data set
type, including paired and unpaired T tests and
two-way ANOVA. Significance values are reported as
follows: p < 0.05*, p < 0.01**, p < 0.001*** and p < 0.0001***.
Error bars are mean ± SEM.
Results
LPS treatment induces the loss of the presynaptic protein
synaptophysin
OHSCs were created from P6-P9 wild-type mice such
that two separate culture dishes (each with three hippo-
campal slices) were generated per animal. Cultures were
aged for 14 days in vitro before treatment with 200 ng/ml
LPS. Slices were collected for western blot or qPCR ana-
lysis after 7 days of treatment. For all analysis, LPS-treated
cultures were directly compared to the untreated control
from the same animal. Figure 1a shows a representative
western blot where lysates were probed for the presynap-
tic protein synaptophysin (SYP), post-synaptic protein
PSD95 and neuronal microtubule protein beta iii tubulin
(Tuj1). Synaptic protein levels were normalised to Tuj1, in
order to control for any loss of neurons that may con-
found any specific vulnerability of the synapses, and propi-
dium iodide staining confirmed that cell death after LPS
treatment was minimal (Additional file 1: Figure S 1). LPS
treatment resulted in a significant loss of synaptophysin
(**p = 0.0051) (Fig. 1b) but did not alter the levels of
PSD95 (p = 0.32) (Fig. 1c). Interestingly, qPCR analysis re-
vealed a significant decline in both synaptophysin (Fig. 1d)
(*p = 0.014) and PSD95 (Fig. 1e) (*p = 0.012) transcript
relative to three housekeeping genes (Pgk1, Ywhaz, Hprt).
The decline in PSD95 transcript may predict eventual
protein decline on the post-synaptic side. Thus, LPS
applied directly to isolated brain tissue disrupts syn-
aptic protein content with presynaptic changes pre-
ceding those on the post-synaptic side.
LPS-induced synaptophysin loss is microglial dependent
To test whether microglia mediate the effect of LPS
directly on brain tissue, these cells were depleted from
slice cultures using the specific toxin clodronate [30, 52,
53] at 13 days in vitro. Twenty-four hours later, half of the
cultures received 200 ng/ml LPS resulting in four treat-
ment groups: control (no treatments), LPS only, clodro-
nate only and clodronate + LPS. Cultures were harvested
at 21 days in vitro (7 days after LPS treatment) (Fig. 2f).
Immunofluorescence staining for the microglial marker
Iba1 revealed a change in morphology and increase in
Iba1 area after LPS addition (Fig. 2a–e). Whilst the micro-
glia detected in untreated (control) OHSCs were in a
ramified, branched state (Fig. 2a), LPS treatment (in the
absence of clodronate) resulted in an increase in total area
of Iba1 signal as well as a shift to an amoeboid morph-
ology (Fig. 2b). Pre-treatment with the microglial toxin
clodronate resulted in almost complete depletion of recog-
nisable microglia, even in the presence of LPS (Fig. 2c, d),
even though some narrow processes remained. The effect
on LPS-induced synaptophysin loss was assessed by west-
ern blot (Fig. 2g) with the results showing that
pre-treatment with clodronate before LPS addition could
block the loss of synaptophysin protein (Fig. 2h). Whilst
OHSCs treated with LPS in the absence of clodronate
showed a significant reduction in synaptophysin (*p =
0.03), there was no difference between clodronate-treated
and clodronate + LPS-treated synaptophysin levels (p =
0.47). There was a significant rescue of synaptophysin
levels when comparing LPS-treated to clodronate +
LPS-treated cultures (***p < 0.001). This rescue indi-
cates a role of OHSC microglia in the effect of LPS on
presynaptic proteins in a system where any effects of clo-
dronate on peripheral cell types [30] can be excluded. It is
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interesting to note that as well as preventing the
LPS-induced synaptophysin loss, the addition of clodro-
nate regardless of LPS treatment increased the levels of
synaptophysin protein (two-way ANOVA effect of clodro-
nate ****p < 0.0001) suggesting a role for microglia in regu-
lating basal levels of synaptic protein in our OHSC model.
To examine whether synaptophysin loss could be
prevented by targeting microglia after application of
the inflammatory insult, to model a clinical situation
where inflammation is treated after it has already
occurred, clodronate was applied 24 h after LPS addition,
and cultures harvested after a further 6 days in vitro
(7 days after LPS application) (Fig. 2i). As before,
western blot analysis (Fig. 2j) showed that there was a
significant depletion in synaptophysin resulting from
LPS treatment alone (*p = 0.019) and a subsequent
treatment with clodronate was able to prevent this
significant difference (p = 0.24) (Fig. 2k). Unlike with
clodronate pre-treatment, however, there was no sig-
nificant rescue when comparing LPS-treated cultures
with and without clodronate (p = 0.11). Thus, treat-
ment after the inflammatory insult is partially effect-
ive but less so than pre-emptive microglial depletion.
IL1β is increased by LPS and is sufficient to induce
synaptophysin depletion in OHSCs
To determine whether a direct action of LPS on brain
tissue causes loss of synaptophysin protein through
Fig. 1 LPS addition causes reduction of synaptophysin protein with no change in PSD95. Fourteen days in vitro organotypic
hippocampal slice cultures were challenged with 200 ng/ml LPS for a further 7 days. Slice cultures were harvested, and synaptic
proteins examined by western blot (a). Seven days of LPS treatment results in loss of the presynaptic protein synaptophysin (**p =
0.0051) (b) but with no change in the post-synaptic protein PSD95 (p = 0.32) (c) (n = 4 per treatment group). There is a significant
decrease in synaptophysin mRNA (*p = 0.014) (d) and PSD95 mRNA (*p = 0.012) (e) after LPS treatment (n = 10 per treatment group). All
statistics were conducted using a paired t test to account for matched control and treated OHSCs from the same animal. Error bars =
mean ± SEM
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Fig. 2 Pre-treatment with clodronate selectively kills microglia and prevents LPS-induced synaptophysin loss. a–d Immunostaining of LPS and
clodronate-treated OHSCs (green = Iba1, blue = Hoechst). Whilst microglia in control conditions appear ramified (a), addition of LPS results in a
striking alteration of microglial phenotype to an amoeboid morphology (b). Pre-treatment of OHSCs with clodronate significantly reduces the
number of recognisable microglia in LPS-naïve cultures (c) and LPS-exposed cultures (d). There is an overall reduction in the area of Iba1
immunostaining after clodronate treatment (*p = 0.024) with an overall effect of LPS to increase Iba1 coverage in OHSCs (*p = 0.034) (e) (n = 4–11
per treatment group). Schematic showing experimental schedule for clodronate pre-treatment (f). Western blot of LPS and clodronate-treated
cultures (g, h) shows that whilst clodronate-naïve cultures show a reduction in synaptophysin when treated with LPS (*p = 0.03) there is no
difference between clodronate pre-treated cultures upon additional LPS application (p = 0.47). There is a significant rescue seen when comparing
the effect of clodronate pre-treatment on cultures treated with LPS (***p = 0.0009). There is a significant overall effect of clodronate treatment
regardless of LPS addition (p≤ 0.0001****) (n = 20 per treatment group). Schematic of experimental protocol for clodronate application after LPS
treatment (i). Western blot (j) shows clodronate-naïve cultures show a loss of synaptophysin when exposed to LPS (*p = 0.019) whereas there is
no difference between clodronate alone versus LPS + clodronate cultures (p = 0.24) (k). There is, however, no significant rescue when comparing
the presence or absence of clodronate in LPS-treated cultures (p = 0.11). There is a significant effect of clodronate regardless of LPS treatment
(*p = 0.036) (n = 18 per treatment group). All statistics were conducted using a two-way ANOVA. Error bars = mean ± SEM
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release of inflammatory cytokines, the concentration of
IL1β in the OHSC medium was determined by ELISA.
Whilst in the untreated culture medium, the levels of
IL1β were undetectable, in LPS-treated cultures, there
was an average of 6 pg/ml IL1β detected, representing a
highly significant increase (***p = 0.0008) (Fig. 3a). This
observation occurs alongside a significant increase in
IL1β mRNA in the slice tissue (**p = 0.0069) (Fig. 3b)
indicating increased transcription of this inflammatory
cytokine. To test whether such downstream production
of IL1β is sufficient to deplete synaptophysin, murine
IL1β protein was applied directly to OHSCs at 14 days
in vitro. After 7 days of 20 ng/ml IL1β, OHSCs were
harvested for western blot analysis (Fig. 3c). As with LPS
treatment (see Fig. 1 and Fig. 2), there is a significant de-
crease in synaptophysin relative to Tuj1 (**p = 0.0081)
(Fig. 3d) and no significant change in PSD95 (p = 0.86)
(Fig. 3e). This demonstrates that IL1β is secreted from
brain-resident cells after LPS treatment and is sufficient
to induce synaptophysin loss in OHSCs.
Microglia-derived IL1β plays a key role in synaptophysin
depletion after LPS treatment
To determine whether the rise in IL1β detected after
LPS treatment originated from microglia, IL1β protein
(Fig. 4a) and mRNA (Fig. 4b) levels were analysed in
Fig. 3 IL1β production is induced by LPS and addition of IL1β results in synaptophysin loss. LPS-treated OHSCs show increased IL1β protein
levels in the culture medium after 24 h (***p = 0.0008) (n = 7) (a). IL1β mRNA is also elevated in 3 weeks in vitro wild-type cultures treated with
LPS for the last week in vitro (**p = 0.0069) (n = 4) (b). Treatment with 20 ng/ml IL1β (c) results in reduced synaptophysin protein (**p = 0.0081)
(d) with no significant change in PSD95 (p = 0.86) (e) (n = 4). All statistics were conducted using a paired t test to account for matched control
and treated OHSCs from the same animal. Error bars = mean ± SEM
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cultures treated with LPS and/or clodronate (as for
Fig. 2). Whilst IL1β was undetectable in the culture
medium of LPS-naïve OHSCs, LPS treatment re-
sulted in detectable levels of this cytokine (Fig. 4a)
(*p = 0.019). Pre-treatment with clodronate resulted
in a significant reduction in IL1β protein in LPS-treated
cultures (**p = 0.0025). Similarly, IL1β mRNA tran-
script was significantly increased after LPS treatment
in clodronate-naïve OHSCs (*p = 0.02), with clodro-
nate pre-treatment significantly lowering transcript
levels to almost undetectable levels (****p < 0.0001)
(Fig. 4b). Taken together, the preservation of synapto-
physin levels seen when microglia are pre-emptively
depleted prior to LPS treatment (Fig. 2) shows a strong
association with the levels of IL1β at both the protein
and mRNA level.
To determine whether IL1β is necessary for LPS to
induce synaptophysin loss, 13 days in vitro OHSCs were
treated with either a murine IL1β-neutralising mouse
monoclonal antibody (α-IL1β) or a mouse IgG isotype
control antibody specific to E. coli β-galactosidase
(α-βGAL). Twenty-four hours later, cultures were treated
with 200 ng/ml LPS. OHSCs were prepared such that the
four different treatment conditions could be compared in
tissue from the same animal. Slices were harvested at 21
days in vitro (7 days after LPS treatment) and analysed by
western blot (Fig. 5a). Whilst OHSCs treated with the
isotype control antibody showed the expected loss of
synaptophysin protein in response to LPS treatment
(*p = 0.02), cultures treated with IL1β-neutralising anti-
body were not sensitive to the addition of LPS (p = 0.83)
(Fig. 5b). There was, however, no significant rescue when
Fig. 4 Depletion of microglia lowers IL1β mRNA and protein. Application of LPS to OHSCs results in a significant increase in IL1β protein in the
culture medium (overall effect of LPS *p = 0.019) which is lowered in cultures pre-treated with clodronate (**p = 0.0025) (n = 5–6 per treatment
group) (a). IL1β mRNA transcript is significantly upregulated in clodronate-naïve OHSCs after LPS treatment (*p = 0.02), but pre-treatment with
clodronate lowers transcript levels to almost undetectable levels (****p < 0.0001) (n = 4–6 per treatment group) (b). Analysis was conducted using
two-way ANOVA. Error bars = mean ± SEM
Fig. 5 Application of anti-IL1β-neutralising antibody alters the OHSC response to LPS. Western blot of antibody and LPS-treated cultures (a)
shows that whilst OHSCs pre-treated with anti-βGAL (control) antibody show a reduction in synaptophysin when treated with LPS (*p = 0.02)
cultures pre-treated with anti-IL1β-neutralising antibody are resistant to LPS addition (p = 0.83) (b). There is no significant rescue of synaptophysin
levels when comparing control antibody +LPS and anti-IL1β antibody + LPS (p = 0.63). All analysis was conducted using a two-way
ANOVA (n = 16 per treatment group). Error bars = mean ± SEM
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comparing LPS-exposed cultures treated with control ver-
sus IL1β-neutralising antibody (p = 0.63), although this is
partly explained by a lowering of baseline synaptophysin
levels by IL1β-neutralising antibody.
Assessing synaptic protein recovery after LPS removal
Next, we sought to determine whether complete removal
of the inflammatory stimulus (LPS) permits recovery of
synaptic protein to untreated levels. This models responses
that may be seen clinically when prophylactic treatment
is not an option. Complete and rapid removal of
inflammatory stimuli from the brain is particularly
difficult to ensure in vivo, but manipulation of the
extracellular environment in this way is straightforward
in OHSCs. OHSCs were prepared such that two culture
dishes were created per mouse (each with three slices).
After 2 weeks in vitro, all of the cultures underwent a 100%
medium exchange, with one of the two dishes receiving
200 ng/ml LPS. After a further week of treatment, one
group of slices (those representing a 0-week post-treatment
timepoint) was harvested for western blot whilst all other
cultures underwent a further 100% medium exchange, re-
ceiving untreated medium. Slices were then left to “recover”
for a further 1 or 2 weeks in vitro (Fig. 6a). Synaptophysin
protein levels in OHSC lysates were analysed by western
blot (Fig. 6b). As expected, OHSCs harvested immediately
after LPS treatment showed a reduction in synaptophysin
protein when compared to untreated slices from the same
animal (*p = 0.014) (Fig. 6c). However, synaptophysin levels
were no longer significantly different in treated vs untreated
OHSCs at 1 week (p = 0.30) or 2 weeks (p = 0.13) after LPS
washout. This indicates that loss of synaptophysin in
response to LPS is substantially reversible after the
inflammatory insult is removed, although the prospect
of a more complete recovery over a longer timescale is
difficult to study in OHSCs due to gradual divergence
from tissue in vivo.
LPS does not cause synaptophysin loss through
alterations to the amyloid pathway
Finally, as inflammation is often linked to increased
cognitive decline in people living with dementia [8], and
Fig. 6 Synaptophysin protein levels undergo recovery after LPS removal. A diagrammatic representation of the LPS recovery experiment (a).
OHSCs are aged for 2 weeks in vitro before undergoing 1 week of 200 ng/ml LPS. At 3 weeks in vitro, some slices are harvested to represent a 0
week after LPS removal timepoint. All other cultures undergo a 100% medium exchange to LPS-free medium. Slices are then harvested at either
1 week or 2 weeks after LPS removal and synaptophysin protein levels assessed by western blot (b). Slices harvested with no recovery after LPS
removal showed a reduction in synaptophysin levels when compared to untreated samples (*p = 0.014). At 1 week (p = 0.30) or 2 weeks (p = 0.13)
after LPS removal, there is no significance between LPS-exposed and untreated OHSCs (c). Analysis was conducted using a two-way ANOVA (n =
5–6 per timepoint and treatment group). Error bars = mean ± SEM
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levels of soluble Aβ have been strongly correlated with
synapse loss [54], we tested the hypothesis that the effects
of LPS on wild-type OHSCs could interact with Alzheimer’s
disease pathogenic mechanisms. We saw no change in APP
mRNA in wild-type OHSCs treated with LPS (p = 0.20)
(Fig. 7a) and neither treatment with LPS (p = 0.053) (Fig. 7b)
nor IL1β (p = 0.56) (Fig. 7c) increased the production of
murine Aβ1–42 (as measured by protein concentration in
the culture medium). Indeed, at later timepoints, LPS treat-
ment significantly reduced the detectable level of Aβ in the
culture medium. This demonstrates that, in the OHSC
system, loss of synaptophysin is not induced by alterations
in Aβ production.
Discussion
Understanding neuroinflammatory mechanisms of synapse
loss is crucial for the development of effective therapeutics
for a wide range of neurodegenerative disorders, but
there are significant challenges to addressing such
mechanisms within the brain. Using isolated brain
tissue maintained for many weeks in culture, we
report a mechanism dependent on microglia and
involving IL1β activity. Loss of synaptophysin occurs
in the absence of significant cell death, alterations in
APP or Aβ production and prior to any change in
PSD95 protein levels. These data confirm, for the first
time, that inflammatory signalling taking place entirely
within brain tissue can lead to presynaptic disruption,
and we present an important new experimental model
for further exploration of mechanisms and therapy.
Our finding that LPS administration results in the loss of
synaptophysin confirms and extends findings previously
reported in vivo [16, 17]. Whilst we do not see alterations
to PSD95 protein under our experimental conditions, a
prior study found application of LPS (at five times the
concentration used here) induced dendritic spine loss in
OHSCs [55]. Our finding that there is a reduction in
synaptophysin and PSD95 mRNA could indicate that
whilst both compartments are sensitive to disruption by
LPS, presynaptic protein disruption occurs earlier and
under lower levels of inflammatory insult, potentially due
to differences in protein turnover rates. Subsequent loss of
dendritic spines could then be a consequence of
deafferentation. These authors do not report having
examined the presynaptic compartment in their work, so it
is feasible that both a pre- and post-synaptic deficit is
present in their model. Likewise, the presence of PSD95 in
a western blot does not prove that this protein exists in
structurally normal spines so we cannot rule out changes
to the organisation of the post-synaptic compartment in
our work.
Taking advantage of the versatility of this model, we
were able to show that depleting microglia in the absence
of any peripheral cell types, prior to LPS insult, prevents
the loss of synaptophysin. This adds considerable weight
to the hypothesis that microglia, and not infiltrating
immune cells from the periphery, are the mediators of
LPS-induced synaptic damage. Specific depletion of
microglia in this system was possible due to the accessibil-
ity of OHSCs to pharmacological manipulation and sim-
plified by the isolation from peripheral circulating
immune cells, whose depletion may induce confounding
effects that could mask the impact on the brain-resident
microglia [30]. We also explored whether microglial de-
pletion 24 h after LPS administration could alter the syn-
aptic response, more closely mimicking potential
treatments, where there may be a delay in identifying the
onset of inflammation. This also prevented a significant
drop in synaptophysin levels when compared to
LPS-naïve OHSCs, but without significant improvement
relative to cultures treated with LPS alone. This indicates
that rapid intervention may be required to completely pre-
vent synapse loss in response to microglial activation, but
some efficacy may be retained at later timepoints.
Our work here supports a pivotal role for IL1β in
inducing hippocampal synaptophysin loss in response to
Fig. 7 LPS does not interact with the amyloid pathway in OHSCs. LPS treatment does not alter APP mRNA expression levels (p = 0.20) (n = 7) (a). ELISA
analysis of OHSC medium reveals that LPS treatment reduces the production of Aβ1–42 (two-way ANOVA: effect of treatment p = 0.053 (n = 4)) (b)
whilst IL1β application does not influence Aβ1–42 accumulation (two-way ANOVA effect of treatment p = 0.56 (n = 4)) (c). Error bars =mean ± SEM
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neuroinflammatory insult. We show, for the first time,
that direct application of IL1β to isolated brain tissue
results in loss of synaptic proteins, mimicking the effect of
LPS addition. Work in acute hippocampal slice cultures has
previously shown that IL1β disrupts synaptic transmission,
abrogates LTD and inhibits LTP [56–59], but we now
extend this to longer term effects on the protein level. This
is important because studies in acute hippocampal
slices take place in highly inflammatory conditions
activated by the slicing injury, which we avoid by
allowing a 2-week settling period prior to experimen-
tation. Thus, even when basal inflammation is low,
IL1β disrupts synapses.
We demonstrate that IL1β at both the protein and
mRNA levels are increased in OHSCs in response to
LPS and this effect is prevented when microglia are
depleted using clodronate. IL1β-neutralising antibody
applied prior to, and throughout, LPS treatment partially
rescues the levels of synaptophysin. Unlike microglial
depletion, the neutralisation of IL1β (and/or other cyto-
kines) is a feasible strategy to protect synapses after an
inflammatory insult in a clinical setting. As the produc-
tion of IL1β increases after LPS addition, and can readily
be detected by ELISA, it may be possible to test patient
blood or CSF samples after a potential inflammatory insult
to assess whether synaptic damage is likely to occur and
treat accordingly. As we did not see a complete rescue
of synaptophysin levels when comparing LPS-treated
cultures with control versus IL1β-neutralising anti-
body, further investigation into additional mediators of
synaptophysin loss may be required. A combinatorial
treatment targeting multiple inflammatory cytokines
might prove a more effective strategy and could be
readily trialled in this system.
Whilst cultures treated with IL1β-neutralising antibody
were resistant to the effects of LPS on synaptophysin
levels, there appeared to be a small effect on basal synaptic
protein levels, which could be responsible for partial res-
cue phenotype seen. Interestingly, a role of IL1β in regu-
lating physiological synaptic processes has been previously
proposed, with studies demonstrating hippocampal en-
richment of IL-1 receptors, enhancement of IL1β produc-
tion after LTP and cognitive deficits induced by IL-1
receptor knockout or IL-1 receptor antagonist administra-
tion to otherwise healthy mice [21, 60–62]. It could be
that application of IL1β-neutralising antibody may itself
impact baseline synaptic processes and should be con-
sidered when designing therapeutics to target IL1β in
neuroinflammation.
Our finding that complete washout of LPS (made possible
by the accessibility of the OHSC system to environmental
manipulation) permits recovery of synaptophysin levels to
approaching that of untreated cultures indicates that
at least partial synaptic recovery is possible if the
inflammatory insult is removed. Whilst studies in
human patients commonly report long-term cognitive
deficits or worsening of neurodegenerative disease
processes after acute inflammatory insults [4], it is
often seen that these patients retain high levels of
circulating inflammatory cytokines [1]. Devising treat-
ments, such as those targeting IL1β that could “reset”
the extracellular environment to a non-inflammatory
state, could be of benefit when seeking to prevent cog-
nitive decline.
Finally, we observe that addition of LPS does not
alter mRNA levels of APP or the production of Aβ in
OHSCs. In fact, Aβ secretion, which is readily testable
in this system, is significantly inhibited over time,
consistent with previous reports that microglia activation
results in increased clearance of diffuse Aβ [26–29].
Whilst some studies report increases in Aβ in response
to neuroinflammatory stimuli [20], the use of different
experimental models and variation in methods of
inflammatory treatment prevent direct comparison. It
seems likely that inflammatory and neurodegenerative
disease processes interact in complex ways and there may
be multiple independent or converging mechanisms that
result in synaptic disruption. Loss of synapses in the brain
is widely reported to correlate with clinical outcome in a
range of neurodegenerative diseases including Alzheimer’s
disease [63–65], amyotrophic lateral sclerosis [66] and
frontotemporal dementia [67]. Understanding mechanisms
by which synapses are lost, and developing therapies
to protect these vital structures, is therefore a key
priority when seeking to develop disease-altering
therapeutics.
Conclusions
In summary, we have shown that the addition of LPS
directly to isolated brain tissue results in loss of the
presynaptic protein synaptophysin in the absence of
significant cell death, changes to PSD95 protein levels
or Aβ production. The depletion of synaptic proteins
can be prevented by pre-treatment with the microglia-spe-
cific toxin clodronate prior to, and to a lesser extent after,
LPS exposure, and recovery begins spontaneously after
rapid and complete LPS removal. There is a
microglial-dependent upregulation of IL1β mRNA and
protein after LPS treatment, and this is sufficient to
induce significant loss of synaptophysin. Application
of IL1β-neutralising antibody protects against the ef-
fects of LPS but may impact basal synaptic processes.
By exploring mechanisms of neuroinflammatory syn-
apse loss in a model system that mitigates unavoid-
able limitations of primary culture and in vivo work,
our study strengthens the evidence for a key role of
microglia-derived IL1β in inducing synaptic dysfunc-
tion after inflammatory insult.
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Additional file
Additional file 1: Figure S1. Treatment with LPS and clodronate does
not result in significant cell death. (a–d) OHSCs were live-stained with
propidium iodide 7 days after LPS treatment (at 21 days in vitro). There
was no significant cell death in control (a), LPS (b), clodronate treated (c)
or LPS + clodronate (d) treated OHSCs. As a positive control, OHSCs
treated with 100% ethanol for 5 min showed extensive propidium iodide
labelling indicating mass cell death (e). (JPG 244 kb)
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